Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Namodenoson - Can Fite Biopharma

Next Previous
Drug Profile

Namodenoson - Can Fite Biopharma

Alternative Names: CF-102; Cl-IB-MECA

Latest Information Update: 05 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institutes of Health (USA)
  • Developer Can-Fite BioPharma; Rabin Medical Center; Temple University School of Medicine
  • Class Amides; Anti-inflammatories; Antifibrotics; Antineoplastics; Antivirals; Hepatoprotectants; Iodobenzenes; Obesity therapies; Purine nucleosides; Small molecules
  • Mechanism of Action Adenosine A3 receptor agonists; Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Liver cancer
  • Phase II Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
  • Preclinical Obesity; Pancreatic cancer
  • No development reported Colorectal cancer; Hepatic fibrosis; Malignant melanoma; Prostate cancer; Reperfusion injury
  • Discontinued Hepatitis B; Hepatitis C

Most Recent Events

  • 05 Apr 2024 9413877: KDM, devT and HE updated.
  • 04 Apr 2024 Can Fite Biopharma submits an IND application with the US FDA in USA for Non-alcoholic steatohepatitis
  • 28 Feb 2024 Can-Fite Biopharma receives Notice of Allowance for use of A3 adenosine receptor ligand in treating ectopic fat accumulation in Canada
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top